Recent publications show how our proprietary SpheroMatrices microTMA technology can be used to understand toxicity risk in discovery safety screenings conducted using 3D microtissues.
2021 Plummer et al, Toxicology Reports:“Species differences in phenobarbital-mediated UGT gene induction in rat and human liver microtissues”
2019 Plummer et al, Toxicology Reports: “Cross-species comparison of CAR-mediated procarcinogenic key events in a 3D liver microtissue model”.
2017 Plummer et al, The Toxicologist, 156, issue 1, abstract ID 2946 “Assessment of Hepatocellular Proliferation in Mouse and Human Hepatocytes in a Novel Humanized FRG KO/NOD Model by Dual Immunofluroescence and Automated Imange Analysis”
2017 Plummer et al, The Toxicologist, 156, issue 1, abstract ID 3204 “Scope and Limitations of Current 3D Spheroid Culture Screening Systems”
2016 Plummer et al, The Toxicologist, 150, issue 1, abstract ID 2455 “Dose Dependent Effects on Rat Liver miRNAs 200a/b and 429: Potential Early Biomarkers of Liver Carcinogenesis”
2015 Plummer et al, The Toxicologist, 144, issue 1, abstract ID 178
2014 Unterberger et al, International Journal of Cancer, 135, 1574-1585
2014 Romer et al, PLOS ONE, 9(5), e97640
2014 Plummer et al, EUROTOX, Edinburgh 7-10 September 2014
2014 Plummer et al, ELRIG Drug Discovery, 2-3 Sept 2014
2014 Plummer et al, The Toxicologist, 138, issue 1, abstract ID 1909
2013 Plummer et al, The Toxicologist, 132, issue 1, abstract ID 1549
2013 Plummer et al, ToxSci 132(2), 443-457
2011 Plummer et al, The Toxicologist, 120, Number S-2, Abstract ID 1041
2011 Chauvigne et al, PLoS ONE 6(11): e27172
2011 Plummer et al, Toxicology Letters, 205, pS31
2010 Elcombe et al The Toxicologist, 114, Number S-1, Abstract ID 2156
on an interactive, step by step basis. Collaborations can begin with pilot projects which can then be scaled up to larger research programs, according to your requirements.
